Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals.

positron emission tomography (PET) --- pyrazoles --- fluorine-18 --- radionuclides --- PET probes --- imaging pharmaceuticals --- hypopharyngeal cancer --- 188Re-liposome --- repeated therapy --- NGS --- microRNA --- aprepitant --- radiopharmaceuticals --- neurokinin 1 receptor antagonist --- radionuclide chelators --- kidney uptake --- cleavable linkers --- neutral endopeptidase (NEP) --- renal brush border enzymes --- prostate-specific membrane antigen (PSMA) --- cancer imaging and therapy --- somatostatin analogs --- radiolabeling --- radionuclide therapy --- imaging --- adrenergic receptor --- positron emission tomography --- radiotracer --- cholecystokinin-2 receptor --- minigastrin --- molecular imaging --- targeted radiotherapy --- lutetium-177 --- EpCAM --- radionuclide --- SPECT --- iodine --- PIB --- breast --- cancer --- PET --- target-specific biomolecules --- immunoPET imaging pharmaceuticals --- production processes --- 124I-labeled monoclonal antibodies --- radiotracers --- AAZTA --- scandium-44 --- FAP --- SA --- DPP --- PREP --- radioiodine labeling --- radioiodination --- biomolecules --- peptides --- proteins --- monoclonal antibodies --- 123,124,125,131I-labeled molecules and biomolecules --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this book, we will cover all the different facets of CTCs to assemble a huge corpus of knowledge on cancer dissemination: technologies for their enrichment, detection, and characterization; their analysis at the single-cell level; their journey as CTC microemboli; their clinical relevance; their biology with the epithelial-to-mesenchymal transition (EMT); their stem-cell properties; their potential to initiate metastasis at distant sites; their ex vivo expansion; and their escape from the immune system.

n/a --- FOLFIRINOX --- immunofluorescence imaging --- AR-V7 --- circulating tumour cells --- chemoradioresistance --- CTC-based treatment decisions --- rVAR2 --- immunophenotyping --- immune system --- CellSearch® --- flow cytometry --- clinical trials --- circulating tumor DNA --- synaptophysin --- stem cells --- colorectal cancer --- melanoma --- CTC biology --- platelets --- AR --- CTC capture technology --- castration resistant prostate cancer (CRPC) --- PD-L1 expression --- rovalpituzumab tesirine --- HMB-45 --- thymidylate synthase --- ctDNA --- tumor cell dissemination --- solid cancers --- metastasis --- locally advanced rectal cancer --- miRNA --- epithelial-to-mesenchymal transition (EMT) --- NSCLC --- tumor biomarkers --- tumor stem cells --- circulating tumor cells --- major histocompatibility complex class I (MHCI) --- bone marrow --- heterogeneity --- cerebrospinal liquid biopsy --- fish --- glioma --- in vivo flow cytometry --- colorectal surgery --- CellSearch --- single-cell analysis --- disseminated tumor cells --- EasyCount slides --- microsatellite instability --- circulating plasma cells --- circulating leukemia cells --- ARV7 --- SLUG --- androgen receptor --- metastatic colorectal cancer --- leukocyte-derived extracellular vesicles --- prostate cancer (PCa) --- neutrophils --- liquid biopsy --- enzalutamide --- CD133 --- enrichment and detection technologies --- biomarkers --- immune checkpoint inhibitors --- biomarker --- RAD23B --- microbiome --- integrin B1 --- ACCEPT --- emboli --- small-cell lung carcinoma --- EPISPOT --- microfluidics --- early breast cancer --- circulating tumor cells (CTC) --- tumor-initiating cells (TICs) --- immunomodulation --- xenograft models --- CTC-derived xenografts --- malaria --- circulating tumor cells (CTCs) --- clinical utility --- exosomes --- liquid surgery --- ctRNA --- CTCs --- epithelial–mesenchymal transition --- targeted therapy --- hematological cells --- gene expression analysis --- hepatocellular carcinoma (HCC) --- breast cancer --- EpCAM enrichment --- prostate cancer --- CTC --- abiraterone --- fibronectin --- CTC-derived ex vivo models --- CTMat --- chromogranin A --- CTM --- exosome --- epithelial-mesenchymal transition